This information collection supports
implementation of section 524 of the Federal Food, Drug, and
Cosmetic Act. The statute provides FDA with authority for awarding
priority review vouchers for future applications to sponsors of
tropical disease product applications that meet the criteria
specified by the Act. We have also developed associated guidance
intended to explain to internal and external stakeholders how we
implement the provisions of section 524.
The information collection
reflects program changes and adjustments. As discussed more fully
in our supporting statement at question 1, FDARA revised
eligibility requirements for the PRVs covered by the information
collection. This results in an increase of 5 responses and 10
burden hours annually. We have also uploaded cost information that,
although previously reported, had not been disclosed at
omb.report.
$7,616
No
No
No
No
No
No
Uncollected
Domini Bean 301 796-5733
domini.bean@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.